Uterine endometrial cancer incidence (~63,200 new cases/year) and deaths (~11,300 deaths/year) are on the rise. To help endometrial cancer patients and cure endometrial cancer, we need understand the characteristics of this disease. The current focus of our work is to understand molecular mechanisms of endometrial tumor progression and utilize target therapy or molecular enhanced hormonal therapy to treat endometrial cancer and other hormone-driven cancers. Specific research initiatives include: 1) systematic dissection of the mechanisms of progesterone receptor (PR) downregulation in endometrial cancer and enhancement of progestin therapy with epigenetic modulators in endometrial cancer, 2) identification of novel small molecular drugs to increase PR expression and activity to sensitize progesterone therapy, 3) targeting the PI3K/Akt/mTOR signaling pathway in endometrial cancer, 4) relationship between the estrogen receptor, progesterone receptor and oncogene Myc in endometrial tumors, and 5) application of molecularly enhanced progestin therapy to other cancer types. Dr. Yang’s laboratory is located in the building of Medical Education Research Facility (MERF).
A strong interest in cancer research is required. Applicants should be independent and scrupulous, with strong organizational skills and good habit to write record. Preference will be given to applicants who plan to pursue advanced training in a related area.
Students must be available for 10 plus hours per week in blocks of time that 4 hours or greater two days a week.
Ongoing or potential to be a continuous position
Volunteer (Optional 0-credit hour course for transcript recognition)
Academic Credit (1-4 semester hours)
How to Apply
If interested, please email Shujie Yang (firstname.lastname@example.org) with your resume/CV and a brief statement of why you're interested in our lab. Please list relevant courses taken and grades.